Latest Neuronetics Stories
Baptist Behavioral Health is offering a new brain stimulation therapy to help people suffering from severe depression who have not had success with antidepressant medications. Jacksonville,
HELSINKI, Finland, September 18, 2014 /PRNewswire/ -- New device to be showcased at two international congresses Nexstim (the "Company"), a
Largest clinical study evaluating durability of treatment with the NeuroStar shows depression patients maintained remission through 52 weeks MALVERN, Pa., Sept.
The North America External Neurostimulation/Neuromodulation Devices Market report defines and segments the concerned market in North America with analysis and forecast of revenue.
Companion health economics analysis shows Transcranial Magnetic Stimulation (TMS) is cost-effective among patients who fail to benefit from prior antidepressant medication NEW YORK,
Neuronetics, Inc. announced today results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy® for Major Depressive Disorder (MDD).
Pilot Study Reveals a Majority of Medication-Free Patients Treated with NeuroStar TMS Experienced Remission After Six Weeks with Durable Effects Through Three Months NEW YORK, May
510(k) filing follows recent FDA clearance of CerenaTMS(TM) SUNNYVALE, Calif. and BALTIMORE, Jan.